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Abstract
Background and objectives Tinnitus is a chronic subjective condition that impacts patients’ health-related quality of life 
(HRQoL) and requires multidisciplinary interventions. In health economics, quality-adjusted life years (QALYs) and will-
ingness to pay (WTP) are essential for evaluating treatment effectiveness in cost-effectiveness, cost-utility, or cost-benefit 
analysis. The extent to which these economic measures have been used in tinnitus research has not been investigated. The 
objectives of this scoping review were to explore findings and limitations of existing studies and provide an insight into how 
these economic measures could be used to quantify the burden of tinnitus in affected individuals.
Methods A scoping review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Anal-
yses (PRISMA) methodological framework. The search strategy involved four electronic databases. Records were included 
when QALYs or WTP were measured in individuals whose primary or secondary complaint was tinnitus.
Results A total of 15 studies were identified: three WTP assessment studies and 12 QALY assessment studies using direct 
preference-based measures (PBMs) (n = 4), indirect PBMs (n = 7), and a disease-specific psychometric instrument (n = 1). 
The limited use to date of PBMs to assess HRQoL in tinnitus patients is an important finding.
Conclusions Further studies using reliable economic methods and focusing on patients’ WTP for treatment or their preference 
for their current health state are needed. Applying PBMs in tinnitus research is crucial not only for the healthcare decision-
making process but also to improve patient-centred care.
Key Points for Decision Makers 
Despite the high economic and societal burden of tin-
nitus, there is as yet no evidence to set the threshold for 
the reimbursement of available treatments.
More multidisciplinary studies assessing quality-adjusted 
life years and the willingness to pay of patients are 
needed to shed light on the burden of this disease, the 
utility of present treatments, and the benefit of novel 
treatments as they are developed.
1 Introduction
In chronic diseases, patient-centred care aims to capture 
patients’ perception and lived experience of the disease, 
associated handicap, treatment expectations, and adaptation 
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mechanisms by assessing their health-related quality of life 
(HRQoL) [1, 2]. Its measurement is crucial for healthcare 
decision-making as it allows the quantification of the bur-
den of the disease and the assessment of the benefits of an 
intervention from the patient’s perspective [3].
Tinnitus, ‘the conscious perception of an auditory sensa-
tion in the absence of a corresponding external stimulus’ [4], 
is an auditory condition that can be chronically experienced 
by patients and can be associated with  negative reactions 
[5, 6], resulting in depression, insomnia, anxiety or other 
comorbidities [7–10]. Each tinnitus patient presents with 
a unique clinical profile characterised by impairments in 
physical, psychological, social, and occupational function-
ing [9, 11–13]. Tinnitus prevalence varies eightfold between 
studies, probably due to the use of different definitions [14]. 
It has been observed that 2–4% of adults have been referred 
to a hospital due to their tinnitus, and 0.5–1% experienced 
limitations in their activities that impact HRQoL [15].
In the absence of a cure to alleviate tinnitus [16], patients 
are oriented toward various healthcare specialists [17, 18] 
and ongoing psychological and non-pharmacological 
approaches such as cognitive behavioural therapy (CBT) 
or tinnitus retraining therapy (TRT) [19], which require 
several sessions and engage recurring costs. Depending on 
tinnitus severity and the adopted clinical management strat-
egy, annual costs of tinnitus care can be substantial: around 
US$660 per patient in the United States [20], €1540 per 
patient in the Netherlands [21], and GB£720 per patient in 
the United Kingdom [22]. It is also important to note that 
there is no established regulatory pathway for tinnitus treat-
ments and no precedent for pricing and reimbursement of 
medications [16].
A wide variety of outcome instruments are used to evalu-
ate the therapeutic benefits of tinnitus treatment [23]. In pub-
licly funded healthcare systems, costs and health outcomes 
appraisals are essential to enable comparability across all 
interventions, assess their value, and guide resource alloca-
tion decisions and prioritisation [24]. The use of disease-spe-
cific outcome measures complicates this process [25]. There 
is as yet no evidence to support the use of disease-specific 
psychometric instruments such as the Tinnitus Handicap 
Inventory (THI) [26], the Tinnitus Functional Index (TFI) 
[27], the Tinnitus Reaction Questionnaire (TRQ) [28], or 
the Tinnitus Primary Function Questionnaire (TPFQ) [6] to 
measure the impact of interventions for tinnitus on HRQoL 
in clinical trials [29–31].
Although there is no international agreement, most 
healthcare systems recommend using quality-adjusted life 
years (QALYs) to capture the health effects of an interven-
tion in cost-effectiveness and cost-utility analyses [32]. 
QALYs result from using measures of HRQoL to adjust life 
years for quality and are defined on a cardinal scale from 0 
(‘dead’ state) to 1 (‘perfect-health’ state) that measures each 
elapsed life year by the health state during this year. One 
QALY represents 1 year in perfect health [33]. QALYs can 
be estimated using direct and indirect approaches. Direct 
estimation is completed using either a ‘choiceless’ meas-
ure (i.e. participants are simply asked to state their values), 
such as the visual analogue scale (VAS), or preference-based 
measures (PBMs), which are choice-based measures, such 
as standard gamble (SG) and time trade-off (TTO) [34]. The 
magnitude of individual preference for each health state 
is expressed through decisions in a series of hypothetical 
scenarios involving risk, uncertainty, and trade-offs, which 
defines its ‘utility’ [35]. Indirect QALY valuation can be 
done using generic PBMs such as the EuroQol (EQ)-5D 
[36], the Short Form 6D (SF-6D)[37], and the Health Utili-
ties Index (HUI) [38] or disease-specific PBMs. These multi-
dimensional instruments take into account direct PBMs in 
their scoring algorithm: TTO for EQ-5D and SG for SF-6D 
and HUI [39, 40].
As an alternative measure, a patient’s willingness to pay 
(WTP) for a QALY quantifies, in monetary value, the ben-
efit of a specific health intervention and its effectiveness for 
cost-benefit analysis [41]. In other words, whereas QALY is 
used to assess patients’ current health status, WTP is used to 
assess changes in health status provided by treatment. WTP 
can be evaluated via open- or close-ended questionnaires. 
Among the various approaches for estimating WTP, the most 
popular is contingent valuation. This method consists of 
providing individuals with a detailed description of a given 
improvement in health (in a hypothetical market) and asking 
them to state the maximum amount they would be willing to 
pay or the minimum amount they would be willing to accept 
in compensation for deprivation [42–44].
In a review to estimate the cost-effectiveness of tinnitus 
management in the UK, Stockdale et al. [22] indicated that 
there are no directly relevant studies allowing the estimation 
of QALYs associated with HRQoL improvement in tinnitus 
research. The primary objective of this study is to review 
studies that measured QALYs and WTP in tinnitus patients. 
A secondary aim is to identify research gaps and insight into 
how these economic measures could be useful in quantify-
ing the burden of tinnitus in affected individuals. A scop-
ing review was considered the most relevant methodology 
to describe evidence research gaps and achieve study aims 
[45, 46].
2  Methods
Throughout this scoping review, a six-step methodologi-
cal framework was followed. This involved (1) setting the 
research question; (2) identifying studies using an in-depth 
literature search; (3) selecting relevant studies through 
screening; (4) extracting and charting of the data; (5) 
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collating, summarising, and reporting the results; and (6) 
consulting with an expert clinician who did not take part in 
stages 1–5 [47].
2.1  Identifying the Research Question
This study was guided by the following research question: 
What is the extent of research with QALYs and WTP in tin-
nitus and the benefits and limitations of their use in quantify-
ing the burden of tinnitus in affected individuals?
2.2  Defining the Search Strategy and Study 
Selection
Records for inclusion were identified from the results of 
electronic database searches. Search terms were tested and 
refined before conducting the final literature search by carry-
ing out a limited search in the database MEDLINE to ensure 
relevant titles and abstracts were obtained. A search of the 
following electronic databases was implemented: MED-
LINE, EMBASE, PsycINFO using the OvidSP platform, 
and Cumulative Index to Nursing and Allied Health Litera-
ture (CINAHL). Database searches were carried out in May 
2020 using a specific search term strategy for each database 
(Table 1). Reference lists of included studies were manually 
searched to further identify relevant records for inclusion. 
No date limit was applied to ensure that all records of inter-
est were obtained. All identified results were downloaded 
with citations, titles, and abstracts and imported into the 
reference manager Endnote X8.2. Articles were screened 
for duplicates, which were then removed.
2.3  Eligibility Criteria
Records were included if QALYs or WTP were used to 
quantify the burden of tinnitus in individuals whose primary 
or secondary complaint was current tinnitus. We searched 
for (1) indirect PBMs, i.e. one of the five groups of generic 
preference-based HRQoL instruments, namely Assessment 
of Quality of Life (AQoL), EQ-5D, HUI, Quality of Well-
Being Scale (QWS), and SF-6D; (2) direct PBMs such as 
TTO and SG; (3) WTP studies; and (4) cost-effectiveness 
or cost-utility or cost-benefit analysis and health valuation 
and utility studies. Eligible records included randomised 
controlled trials (RCTs), cohort studies, and cross-sectional 
studies. Papers were included from all age groups and all 
countries, if available in English. Records were excluded 
when tinnitus and health state valuation measures were not 
reported.
2.4  Inclusion Criteria
Inclusion criteria were applied in two stages. In the first 
stage, titles and abstracts of included texts were screened 
independently using an iterative approach by two researchers 
(ED, CC). Articles were retained during phase one if the title 
and abstract included a reference to primary or secondary 
tinnitus and the health state valuation measures described 
above (or alluded to broader terminology, such as ‘QALY’ 
or ‘utility’ or ‘WTP’). Full texts were retrieved for records 
Table 1  Search term strategies for database searches
CINAHL Cumulative Index to Nursing and Allied Health Literature
MEDLINE, EMBASE and PsycINFO CINAHL
1 (economic OR economic analysis).ti,ab Economic OR economic analysis
2 (willingness to pay OR wtp OR cost benefit OR cost effectiveness 
OR cost utility).ti,ab
Willingness to pay OR wtp OR cost benefit OR cost effectiveness OR 
cost utility
3 (time trade off OR tto OR standard gamble OR sg).ti,ab Time trade off OR tto OR standard gamble OR sg
4 (QALY OR quality adjusted life years OR health valuation OR 
health utilit*).ti,ab
QALY OR quality adjusted life years OR health valuation OR health 
utilit*
5 (EuroQ*OR EQ 5D OR EQ 5D* OR EQ? 5D).ti,ab EuroQ*OR EQ 5D OR EQ 5D* OR EQ? 5D
6 (HUI OR Health Utilities Index).ti,ab HUI OR Health Utilities Index
7 (Quality of Wellbeing OR Quality of Well-Being OR QWB OR 
QWB-SA).ti,ab
Quality of Wellbeing OR Quality of Well-Being OR QWB OR 
QWB-SA
8 (AQoL OR assessment of quality of life).ti,ab AQoL OR assessment of quality of life
9 (SF-6D OR SF6D).ti,ab (SF-6D OR SF6D).ti,ab
10 (15D OR 16D OR 17D OR 15 dimensional OR 16 dimensional OR 
17 dimensional).ti,ab
15D OR 16D OR 17D OR 15 dimensional OR 16 dimensional OR 17 
dimensional
11 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10
12 tinnitus tinnitus
13 11 AND 12 11 AND 12
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that the researchers agreed were eligible for full-text screen-
ing in the second stage. The screening was performed inde-
pendently by two researchers (ED, CC) and involved the 
hierarchical application of exclusion criteria. First, articles 
were excluded if study participants did not have tinnitus. 
Second, records were excluded if the health state valuation 
measures described above were not used. If there was a dis-
agreement between researchers regarding the inclusion of 
records in this review, a third researcher (DB) was consulted 
to arbitrate.
2.5  Data Extraction
Data were extracted independently by two researchers (ED, 
CC) for each record. The following items were included in 
data extraction: name of the authors, year of publication, 
the title of the study, country, study design, study popula-
tion, age of participants, sample size, number of participants 
with tinnitus, tinnitus type, study aim, the method selected 
for QALY or WTP measurement, justification of method 
selection, psychometric evidence of selected instruments 
(correlation with a disease-specific questionnaire used to 
assess tinnitus severity), authors’ concerns regarding the 
use of tools, mean health state values specific to tinnitus, 
and any notes (or limitation) of included records. Any disa-
greements in data extraction were reviewed, and a final data 
set was decided.
3  Results
A total of 245 individual results were identified from the 
database search. Title and abstract screening resulted in the 
exclusion of 222 records. After reviewing the full text of 
the remaining records, 15 were included (see Fig. 1). Their 
details are summarised below in the ‘Study Characteristics’ 
subsection. The subsections report the studies of relevance 
to the primary question (‘Main Findings’) and the secondary 
questions (‘Research Gaps’).
Fig. 1   PRISMA flow chart of 
the study selection process. 
CINAHL Cumulative Index 
to Nursing and Allied Health 
Literature, PRISMA Preferred 
Reporting Items for Systematic 
Reviews and Meta-Analyses, 
QALY quality-adjusted life year, 
WTP willingness to pay
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3.1  Studies Characteristics
The studies were categorised as WTP assessment (n = 3) 
and QALY assessments using direct PBMs [48–51] (n = 
4), indirect PBMs [52–58] (n = 7), and disease-specific 
psychometric instrument [59] (n = 1). The characteristics 
and demographics of these studies are detailed in Table 2. 
We made two decisions to link studies. First, the study by 
Maes et al. [53] was performed on the same study popula-
tion recruited for the RCT [52] and was followed by cost-
effectiveness analysis [54]. Based on this disclosure made 
by the authors themselves, it was decided to merge the evi-
dence reported in these studies. Second, after comparing 
author names, location and setting, numbers of participants 
and baseline data, date and duration of the study [60], it was 
decided to link together complementary findings from mul-
tiple reports [49–51] of the first cross-sectional study from 
Happich and Mazurek [48].
3.2  Main Findings
3.2.1  Methods Used for Health State Valuation
In available studies [61–63], participants’ WTP for treat-
ment was assessed via close-ended questionnaires. In two 
studies [61, 62], choices given to participants’ comprised 
the following WTP categories: US$1000, US$5000, 
US$10,000, US$25,000, and US$50,000. In Smit et al. 
[63], the options to be considered were listed as a propor-
tion of the participant’s monthly income and ranged from 
less than one fourth to more than 20 times.
Various generic preference-based HRQoL instruments 
were used to calculate QALYs: HUI2 (n = 1) [58], HUI3 
(n = 2) [53, 58], EQ-5D (n = 3) [53, 57, 58], SF-6D [58] 
(n = 1), and QWS (n = 2) [55, 56]. Another study [59] 
calculated the cost of treatment per QALY using the THI 
based on a specific formula [64]: QALYs were estimated 
by multiplying the life expectancy (the difference between 
Table 2  Demographics and characteristics of included articles
QALY quality-adjusted life year, WTP willingness to pay
References # Authors Date Country Measure Study design Type of tinnitus 
complaint




[61] Engineer et al. 2013 USA WTP Cross-sectional Non-specified 47.4
25–65
439
[62] Tyler 2012 USA WTP Cross-sectional Non-specified 66.4
31–90
197
[63] Smit et al. 2018 The Netherlands WTP Cross-sectional Non-specified 58 (12)
18–64
415
[48] Happich and 
Mazurek
2002 Germany QALYs Cross-sectional Non-specified 54
16–85
420
[49] Happich and Mue-
hlbacher
2003
[50] Happich and von 
Lengerke
2005
[51] Happich et al. 2009







[53] Maes et al. 2011
[54] Maes et al. 2014
[59] Newman and San-
dridge








[58] Summerfield et al. 2019 UK QALYs Prospective, longi-
tudinal study
Tinnitus associ-











[55] Robinson et al. 2005 USA QALYs Randomised con-
trolled trial
Non-specified 57 115
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chronological age and projected life expectancy [65]) with 
the difference score (pre- and post-fitting) on the THI. 
Direct non-PBMs (VAS) and PBMs (SG, TTO) were also 
used [48]. The use of AQoL instruments has not been con-
sidered in tinnitus research.
3.2.2  WTP and Mean Health State Values
Both studies [61, 62] show the most selected WTP category 
to reduce tinnitus by half was US$1000 for all respond-
ents, and the most chosen WTP category to eliminate it 
was US$5000. Engineer et al. [61] show that 63.2% of the 
‘very loud’ subgroup would pay more than US$10,000 to 
eliminate tinnitus, and 26.7% of those are willing to pay 
US$50,000. However, in both studies, patients’ financial sta-
tus, which directly influences their WTP, was not measured 
[62]. Smit et al. [63] found that 58% of participants would be 
willing to pay more than their total monthly income to cure 
tinnitus. Of the participants with a slightly lower age range, 
25% reporting a significantly higher tinnitus loudness, bur-
den, and associated psychological distress would be willing 
to pay 20 times their monthly income for a cure.
For QALY assessment, three studies reported at least one 
mean health state valuation for tinnitus alone. Two studies 
reported mean utility scores using QWB, respectively, for 
two different samples of the same study at baseline [55, 56]. 
Another study [53] showed lower utility scores with HUI3 
(0.63) than with EQ-5D (0.77) at baseline. Although, in gen-
eral, the TTO (used for the EQ-5D) leads to lower scores 
than the SG (used for the HUI3) [66], authors explained that 
while the utility scoring function of the EQ-5D is additive, 
assuming no interaction for preferences among attributes at 
all, the HUI3 uses a multiplicative scoring function, with the 
effect on the index of a change in the level of one attribute 
depending on the levels of other attributes. The utility scores 
of the HUI3 were expected to be lower because they take 
into account the effect of comorbidity. In general, low utility 
scores found at baseline (before interventions) indicate that 
tinnitus is a relatively high burden to affected patients. One 
study [48] using direct measures to value QALYs found that 
patients, in general, assign higher utilities to their condition 
than unaffected people asked to rate this condition. This dif-
ference in QALYs was more pronounced for VAS (0.53 vs 
0.34) than for SG (0.88 vs 0.80) and TTO (0.83 vs 0.78). 
The authors explained that, on average, disease sufferers are 
less willing to take risks than unaffected persons. They also 
stated that formulating an accurate description of a tinnitus 
patient’s subjective experience that the general public can 
adequately understand is challenging.
3.3  Research Gaps
3.3.1  Appropriateness of Elicitation Methods
Studies reported WTP estimates per subgroup based on 
the patient’s evaluation of tinnitus loudness and associated 
annoyance on a VAS [62] or a Likert scale question [61]. 
One study [62] found a significantly low correlation between 
WTP to eliminate tinnitus and tinnitus loudness (r = 0.263, 
p < 0.001) and annoyance (r = 0.284, p < 0.001). However, 
the authors of both studies cautioned on the interpretation 
of WTP valuations because open-ended questionnaires were 
not provided, and the given category choices could influence 
the responses.
For QALY indirect assessment, two studies examined 
aspects of validity and feasibility of generic PBMs for tin-
nitus. Maes et al. [53] compared HUI3 and the three-level 
version of EQ-5D (EQ-5D-3L) and concluded that although 
both utility measures discriminate between clinically dif-
ferent groups, the ceiling effects were more frequent in the 
EQ-5D health state descriptions. The HUI3 also shows a 
significant effect on the hearing and cognition dimensions. 
The authors also examined whether a change in mean util-
ity scores with the HUI3 or EQ-5D was accompanied by a 
change in a tinnitus psychometric questionnaire [the Tinnitus 
Questionnaire (TQ)] [53] and concluded that the HUI3 was 
slightly more responsive than the EQ-5D. Besides, one study 
[58] confirmed that EQ-5D-3L was more sensitive to the 
slight improvement in tinnitus discomfort (measured with a 
Likert-based questionnaire) after cochlear implantation. The 
authors suggested that the decision to use HUI3 or EQ-5D 
depends on policymakers’ preferences in different jurisdic-
tions. They also commented that SF-6D was insensitive to 
change in tinnitus and hearing impairment. In Stephens et al. 
[57], EQ-5D did not capture the perceived consequences of 
tinnitus in the HRQoL of patients with Menière’s disease. In 
Robinson et al. [55], tinnitus severity was measured explic-
itly using a psychometric questionnaire (Tinnitus Handicap 
Questionnaire [THQ]), and the authors concluded that the 
QWS was insensitive to changes in tinnitus. Robinson et al. 
[56] found that while tinnitus-related aspects of HRQoL 
(measured with the TRQ) and depression [measured with 
the Beck Depression Inventory (BDI)] were improved with 
treatment, the QWS score did not change.
3.3.2  Justifications for Instrument and Respondent 
Selection
In Engineer et al. [61], the justification for using a closed-
ended questionnaire to assess patients’ WTP was based on 
pilot studies indicating that open-ended formats were more 
challenging to perform. However, authors [61] suggested 
that other forms of questions with increased uncertainties 
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or prompting respondents to consider the potential risks of 
treatments could influence their responses. Besides, there 
was no justification for setting the lowest cut-off category at 
US$1000 in either study. For QALY assessment using direct 
PBMs [48–51] and indirect PBMs [52–58], the authors gave 
a general overview of the methods used without stating any 
tinnitus-specific justification. One study [53] provided a 
tinnitus-specific explanation commenting that the hearing 
and cognition dimensions in HUI3 are likely to be relevant 
for tinnitus patients. Resulting RCT [52] and cost-effec-
tiveness analysis [54] studies using HUI3 cited the results 
drawn from [53], which found adequate responsiveness 
associated with this index in the tinnitus population. The 
justification provided by Newman and Sandridge [59] for 
the use of the THI to calculate QALYs was that the THI 
meets the requirements as an appropriate outcome measure 
for economic analyses [67] because of ‘its capacity to assess 
changes in HRQoL associated with tinnitus.’ However, the 
THI is criticised for lacking sensitivity to change [31, 68]. 
The authors were concerned that the results were obtained 
from the selected samples (tinnitus self-help group [62], 
members of a society of tinnitus patients [63], street sample 
[48]) and therefore could not be extrapolated to the general 
tinnitus population. The main findings and the research gaps 
discussed above are summarised in Table 3.
4  Discussion
Compared to other chronic diseases  [70, 71], the lack of 
economic evaluation studies in tinnitus research is an essen-
tial finding of this scoping review. The variations in WTP 
and mean health state values between studies make it dif-
ficult to draw definitive conclusions and calculate WTP per 
QALY. QALYs and WTP valuation studies are necessary for 
resource allocation purposes. A consistent design, including 
a justification of the elicitation method used, reporting of 
respondents’ characteristics, and framing of questions and 
response options, is crucial to allow the generalisability of 
the results. First, we discuss the findings and limitations of 
available studies on QALY and WTP and new directions 
for future research. Second, we discuss the utility of these 
economic measures in quantifying the burden of tinnitus in 
affected individuals.
Although it is impossible to draw any general conclu-
sion from the three WTP studies, available data showed 
that patients with severe tinnitus would be willing to pay 
around an average annual salary in their countries [61, 63]. 
Compared to the costs [17, 18], these amounts are relatively 
high, indicating a potential economic benefit in finding a 
tinnitus treatment. Concerning the limitations, the fact that 
the majority of patients have paid less than US$500 in the 
past [45] makes the minimal category of payment scale set 
at US$1000 questionable [57, 59]. As the choice of WTP 
categories in close-ended questionnaires could influence 
the respondent’s response, open-ended questionnaires ask-
ing respondents to give a range of WTP instead of a specific 
amount could reduce the risk of bias [72]. WTP valuation 
is influenced by socio-demographic factors, including the 
nature of the healthcare system (private/public) or income 
[69], which should be considered. The use of generic PBMs 
(EQ-5D, HUI3, SF-6D, and QWS) was limited to four 
studies. The SF-6D was found to be insensitive to tinnitus 
changes in one study. However, the SF-36, from which the 
SF-6D was derived, has been extensively used in tinnitus 
research and was able to capture changes in tinnitus sever-
ity [15, 73, 74]. More research is needed to conclude on 
its performance in the tinnitus population. In contrast to 
domains included in other generic preference-based instru-
ments such as EQ-5D (Mobility, Self-Care, Usual Activities, 
Pain/Discomfort, Anxiety/ Depression) and SF-6D (Physi-
cal Functioning, Role Limitations, Social Functioning, Pain, 
Mental Health, Vitality), the HUI2/3 systems (Vision, Hear-
ing, Speech, Ambulation, Dexterity, Emotion, Cognition, 
Pain) are based on measures reflecting functional capacity 
instead of performance [75]. In theory, the HUI3, which 
is the only instrument covering speech and cognition, may 
allow a more appropriate description of the tinnitus popula-
tion. In some jurisdictions, guidelines recommend the use of 
EQ-5D unless the latter is proven inappropriate. Comparing 
the HUI and the EQ-5D using the THI, could provide an 
answer. If generic PBM instruments are not sufficiently sen-
sitive to evaluate tinnitus-related QALYs, a disease-specific 
preference-based questionnaire may be used as an alternative 
[32]. A disease-specific preference-based questionnaire for 
tinnitus does not exist and could be developed by mapping 
the items of a disease-specific instrument (THI or TFI) onto 
the utility algorithm of a generic instrument such as the 
EQ-5D [76, 77]. This procedure has already been done in 
vision research [78, 79]. Evaluating HRQoL using PBMs in 
clinical trials can provide insight into treatment effectiveness 
and advantages even before performing cost-effectiveness 
analysis, reduce sample size during economic analysis, or 
facilitate a subsequent cost-utility analysis following an RCT 
[80, 81].
Recognizing  what affected aspects of HRQoL mat-
ter more to patients would help clinicians and researchers 
understand their treatment preferences and subsequent sat-
isfaction and adherence [82]. Psychometric instruments, 
which are currently used to measure tinnitus burden, equally 
weigh HRQoL domains without considering their relative 
significance, interactions, and contribution to the burden of 
the disease from the patients’ perspective. In comparing two 
treatments, each might perform better against one dimen-
sion, making it harder to determine which treatment was 
more effective [83]. PBMs mainly aim to capture patients’ 
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preferences and treatment expectations and might be used 
in clinical research to provide information on the degree 
to which tinnitus affects a patient (using TTO or SG) and 
estimating the potential value that a given treatment may 
provide (using WTP). Understanding the burden can also 
be done by comparing tinnitus with other chronic diseases. 
For example, the pathophysiological similitudes between 
chronic pain and tinnitus have been highlighted in the lit-
erature [84–86]. Comparing TTO and SG of tinnitus and 
chronic pain or WTP for tinnitus and chronic pain treatments 
may shed light on similarities in their impact on HRQoL. 
Besides, as patients’ attitude toward risk is involved in direct 
QALY valuation [35] and might be influenced by their traits 
and treatment expectations [87], one hypothesis to test, using 
direct QALY valuation methods, is whether higher tinnitus 
severity leads to more risk-averse behaviour toward trying 
new therapies. Finally, individuals’ demographic (cultural) 
and socioeconomic characteristics influence QALY valua-
tion [88] and provide some direction concerning how the 
burden of hearing-related diseases, including tinnitus, could 
be differently perceived in different cultures (depending on 
these environmental factors).
A limitation of this review is the possibility that the 
search strategy could have overlooked relevant articles. Sys-
tematic searching can be challenging in studies involving the 
measurement of HRQoL outcomes, considering the absence 
of formal indexing standards in databases and the authors’ 
inconsistent reporting style. Only documents in English were 
included. Some studies that used health state valuation meth-
ods written in other languages might have been missed.
5  Conclusion
This study highlights the limited use of economic measures 
in tinnitus research and the methodological shortcomings 
of available studies. There is no evidence to support the cal-
culation of WTP per QALY for a tinnitus treatment, which 
presently impedes the resource allocation process. More 
studies estimating the correlation between generic PBMs 
and psychometric treatments and establishing head-to-head 
comparisons of generic PBMs are urgently required to assess 
which of these is more sensitive to distinguish tinnitus suf-
ferers according to the severity of their symptoms and which 
dimensions/attributes of the generic PBMs underpin sensi-
tivity to tinnitus and to treatments that alleviate it.
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